Bone Biologics CORP

Bone Biologics Corporation provided a mid-year update highlighting progress in its NB1 clinical development, manufacturing readiness, and intellectual property initiatives, supported by a recent $3.0 million financing.

Bone Biologics Corporation has postponed its 2026 annual meeting of stockholders to September 28, 2026, to include an additional proposal for stockholder consideration.

Bone Biologics Corporation announced the pricing of a private placement of common stock (or pre-funded warrants) and Series F and G warrants, raising approximately $3.0 million in upfront capital.

Bone Biologics Corporation announced a new prospectus supplement for an at-the-market offering to sell up to $1.064 million of common stock.

Bone Biologics Corporation summarized its 2025 operational, scientific, and corporate achievements and outlined its strategic plans for 2026.

Bone Biologics CEO Jeffrey Frelick issued a letter to stockholders detailing progress on NB1, clinical study milestones, and financial runway.

Bone Biologics Corporation reported a net loss of $765,988 for Q1 2026, with a significant decrease in research and development expenses, while general and administrative costs rose.

Bone Biologics Corporation reported a narrower net loss and increased cash reserves for Q3 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Bone Biologics Corporation reported increased cash reserves and progress in its clinical trials, despite continued net losses and ongoing going concern doubts.

Bone Biologics Corporation announced its Q1 2025 financial results, highlighting increased research and development spending and addressing a Nasdaq deficiency notice regarding its minimum bid price.

Bone Biologics Corporation announced its third quarter 2024 financial results, highlighting a decrease in research and development expenses and the commencement of a pilot clinical study for its NB1 bone graft device.

Bone Biologics Corporation announced its second quarter 2024 financial results, highlighting a decrease in operating expenses and the commencement of a pilot clinical study for its NB1 bone graft device.

Bone Biologics Corporation reports recurring operating losses and substantial doubt about its ability to continue as a going concern, despite progress in its spinal fusion clinical study and recent capital raises.

Bone Biologics Corporation reports its financial results for the year ended December 31, 2024, highlighting ongoing clinical trials and financial activities.

Bone Biologics Corporation's 2023 annual report reveals a significant increase in research and development expenses and a net loss, raising concerns about the company's ability to continue as a going concern.

Bone Biologics Corp's CFO, Deina Walsh, was granted 8,335 employee stock options with an exercise price of $1.55, effective January 8, 2026.

Bone Biologics Corp's CEO, Jeff Frelick, reported the acquisition of new employee stock options and beneficial ownership of common stock.

Bone Biologics Corp. Director Phillip Meikle II was granted 62,894 non-employee stock options at an exercise price of $0.88, vesting quarterly over one year.

Bone Biologics Corp. Director Siddhesh Rajendra Angle reported the grant of new stock options and updated his beneficial ownership of derivative securities in a recent SEC Form 4 filing.

Bone Biologics Corp. Director Bruce Stroever was granted 62,894 non-employee stock options with an exercise price of $0.88, vesting quarterly over one year.

Bone Biologics Corp. Director Robert E. Gagnon has reported the acquisition of 62,894 non-employee stock options at an exercise price of $0.88, granted on June 4, 2025, under the company's 2015 Equity Incentive Plan.

Bone Biologics Corporation announces its 2026 Annual Meeting of Stockholders to be held on August 11, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Bone Biologics is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Bone Biologics Corporation has filed a definitive proxy statement with the SEC.

Bone Biologics Corporation will hold its 2024 Annual Meeting of Stockholders on September 17, 2024, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

Bone Biologics Corporation announced a public offering of common stock and warrants to raise approximately $4.3 million, aiming to fund clinical trials and patent portfolio expansion, while acknowledging substantial doubt about its ability to continue as a going concern.

Bone Biologics Corporation files an amendment to its S-1 registration statement, primarily to include updated exhibits related to an engagement agreement with H.C. Wainwright & Co., LLC.

Bone Biologics Corporation aims to raise capital through an offering of common stock, warrants, and pre-funded warrants, targeting clinical trials and patent portfolio expansion.

Bone Biologics Corporation is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common warrants, aiming to fund clinical trials and extend its patent portfolio.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Bone Biologics Corporation as of September 30, 2025.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% beneficial ownership stake in Bone Biologics Corporation's common stock as of July 3, 2025.